March 24, 2018 4:51 AM ET


Company Overview of Obsidian Therapeutics, Inc.

Company Overview

Obsidian Therapeutics, Inc. develops regulated cell and gene therapeutics. The company was founded in 2015 and is based in Cambridge, Massachusetts.

400 Technology Square

10th Floor

Cambridge, MA 02139

United States

Founded in 2015



Key Executives for Obsidian Therapeutics, Inc.

Obsidian Therapeutics, Inc. does not have any Key Executives recorded.

Obsidian Therapeutics, Inc. Key Developments

Obsidian Therapeutics, Inc. Announces Presentation of Preclinical Data on its Technology Platform and Applications

Obsidian Therapeutics, Inc. announced the presentation of preclinical data on its technology platform and applications at the Keystone Symposium on Emerging Cellular Therapies. The presentation includes initial in vivo proof of concept data demonstrating Obsidian’s strategy for precise pharmacologic control of cell therapy by employing destabilizing domains (DDs), which are small, fully-human protein domains that confer conditional stability to a fused payload protein. The Keystone presentation describes the successful implementation of DD technology in engineered primary human T cells and demonstrates ligand-controlled regulation of cytokine protein expression in vitro and in vivo to enhance CAR-T function. These data demonstrate the feasibility of exogenous control over transgene-derived protein expression in primary human T cells for the development of next-generation CAR-T cell products with enhanced efficacy and more favorable safety profiles. Data presented at the meeting include: - Destabilizing domain (DD) technology enabled titratable and reversible regulation of protein levels in preclinical studies, using FDA-approved small-molecule drugs as pharmacologic regulators. - The studies demonstrated small-molecule control of DD-mbIL15 and DD-IL12 “cassettes” in human T cells in vitro. - Systemic IL12 levels from transduced T cells were regulated in vivo with pulsatile dosing and precise dose-response. - A range of DD variants were used in the studies, with performance characteristics matched to specific applications. - These studies represent in vivo proof of concept for the ability to create next-generation CAR-T cell products that provide precise control over transgene-derived protein expression, with the potential to offer enhanced efficacy and more favorable safety profiles.

Obsidian Therapeutics, Inc. Presents at Keystone Symposia Conference, Feb-11-2018

Obsidian Therapeutics, Inc. Presents at Keystone Symposia Conference, Feb-11-2018 . Venue: Keystone Resort, Keystone, Colorado, United States.

Obsidian Therapeutics Announces Management Changes

Obsidian Therapeutics, Inc. named Michael Gilman, Ph.D., as Chief Executive Officer. The company has assembled a strong scientific team: Michael Gilman, Ph.D., CEO of Obsidian Therapeutics, CEO of Arrakis Therapeutics, former founding CEO of Padlock Therapeutics and Stromedix, with executive roles at Biogen and ARIAD Pharmaceuticals; Tariq Kassum, M.D., Senior Vice President, Head of Business Operations, and company cofounder, former leadership roles at Takeda and Millennium Pharmaceuticals; Steve Shamah, Ph.D., Senior Vice President and Head of Research, former leadership roles at Juno Therapeutics and X-Body Biosciences; Vipin Suri, Ph.D., Vice President, Head of Discovery, and company cofounder, former roles at Raze Therapeutics and GSK; Celeste Richardson, Ph.D., Vice President, Cell Therapy, former roles at Novartis Institute for Biomedical Research. The company’s Board of Directors includes: Peter Barrett, Ph.D., Partner at Atlas Venture; Karen Hong, Ph.D., Senior Investment Director at Takeda Ventures, Inc.; Carolyn Ng, Ph.D., Principal, Vertex Ventures HC; Jason Gardner, Ph.D., CEO of Magenta Therapeutics; Michael Gilman, Ph.D., CEO of Obsidian Therapeutics. Observers on the Board of Directors are Blake Byers, Ph.D., General Partner at GV; Michael Gladstone, Principal at Atlas Venture; and Gladys Nunez, M.Sc., Principal, Amgen Ventures.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

Private Placement
November 29, 2017

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
Tax Management Inc United States
John F. Kennedy Center For The Performing Arts United States
NYC2012, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Obsidian Therapeutics, Inc., please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at